Literature DB >> 28956296

The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study.

C Cipriani1, J Pepe2, F Bertoldo3, G Bianchi4, F P Cantatore5, A Corrado5, M Di Stefano6, B Frediani7, D Gatti8, A Giustina9, T Porcelli10, G Isaia6, M Rossini8, L Nieddu11, S Minisola2, G Girasole4, M Pedrazzoni12.   

Abstract

PURPOSE: The study was aimed at evaluating the prevalence of osteoporosis, defined by BMD and the National Bone Health Alliance (NBHA) criteria, and the prevalence of clinical risk factors for fractures in Italian postmenopausal women.
METHODS: This is a cross-sectional, multicenter, cohort study evaluating 3247 postmenopausal women aged ≥ 50 and older in different areas of Italy in the period 2012-2014. All the participants were evaluated as far as anthropometrics; questionnaires for FRAX® and DeFRA calculation were administered and bone mineral density was measured at lumbar spine, femoral neck and total hip by DXA.
RESULTS: The prevalence of osteoporosis, as assessed by BMD and NBHA criteria was 36.6 and 57%, respectively. Mean ± SD values of FRAX® and DeFRA were: 10.2 ± 7.3 and 11 ± 9.4 for major fractures, and 3.3 ± 4.9 and 3.9 ± 5.9 for hip fractures, respectively. Among clinical risk factors for fracture, the presence of previous fracture, particularly non-spine/non-hip fracture, parental history of hip fracture and current smoking were the most commonly observed.
CONCLUSIONS: Our study showed that more that the half of postmenopausal women aged 50 and older in Italy has osteoporosis on the basis of the NBHA criteria. There is a relevant high risk of femur fracture, as assessed by the FRAX® and DeFRA and previous fracture, parental history of hip fracture and current smoking are the most common risk factors. The data should be considered particularly in relation to the need to increase prevention strategies on modifiable risk factors and therapeutic intervention.

Entities:  

Keywords:  DeFRA; FRAX®; Fracture; Italy; Osteoporosis; Risk factors

Mesh:

Year:  2017        PMID: 28956296     DOI: 10.1007/s40618-017-0761-4

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  40 in total

1.  Definition of a population-specific DXA reference standard in Italian women: the Densitometric Italian Normative Study (DINS).

Authors:  M Pedrazzoni; G Girasole; F Bertoldo; G Bianchi; C Cepollaro; A Del Puente; S Giannini; S Gonnelli; D Maggio; C Marcocci; S Minisola; E Palummeri; M Rossini; L Sartori; L Sinigaglia
Journal:  Osteoporos Int       Date:  2003-10-03       Impact factor: 4.507

Review 2.  Clinical use of bone densitometry.

Authors:  C C Johnston; C W Slemenda; L J Melton
Journal:  N Engl J Med       Date:  1991-04-18       Impact factor: 91.245

3.  Assessment of Fracture Risk in A Population of Postmenopausal Italian Women: A Comparison of Two Different Tools.

Authors:  Gloria Bonaccorsi; Enrica Fila; Carlo Cervellati; Arianna Romani; Melchiore Giganti; Maurizio Rossini; Pantaleo Greco; Leo Massari
Journal:  Calcif Tissue Int       Date:  2015-05-05       Impact factor: 4.333

4.  Hypovitaminosis D in an Italian population of healthy subjects and hospitalized patients.

Authors:  E Romagnoli; P Caravella; L Scarnecchia; P Martinez; S Minisola
Journal:  Br J Nutr       Date:  1999-02       Impact factor: 3.718

5.  The effect of parathyroid hormone (1-84) treatment on serum bone morphogenetic protein 4 and vascular endothelial growth factor in postmenopausal women with established osteoporosis.

Authors:  J Pepe; C Cipriani; F P Cantatore; A Fabbri; E Pola; V Vinicola; O Raimo; F Biamonte; R Pascone; C Ferrara; S Minisola
Journal:  J Endocrinol Invest       Date:  2017-02-25       Impact factor: 4.256

6.  Recent trends in hip fracture rates by race/ethnicity among older US adults.

Authors:  Nicole C Wright; Kenneth G Saag; Jeffrey R Curtis; Wilson K Smith; Meredith L Kilgore; Michael A Morrisey; Huifeng Yun; Jie Zhang; Elizabeth S Delzell
Journal:  J Bone Miner Res       Date:  2012-11       Impact factor: 6.741

7.  The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA.

Authors:  N C Wright; K G Saag; B Dawson-Hughes; S Khosla; E S Siris
Journal:  Osteoporos Int       Date:  2016-12-13       Impact factor: 4.507

8.  Objectively Verified Parental Hip Fracture Is an Independent Risk Factor for Fracture: a Linkage Analysis of 478,792 Parents and 261,705 Offspring.

Authors:  Shuman Yang; William D Leslie; Lin Yan; Randy Walld; Leslie L Roos; Suzanne N Morin; Sumit R Majumdar; Lisa M Lix
Journal:  J Bone Miner Res       Date:  2016-04-30       Impact factor: 6.741

Review 9.  Fracture risk associated with smoking: a meta-analysis.

Authors:  P Vestergaard; L Mosekilde
Journal:  J Intern Med       Date:  2003-12       Impact factor: 8.989

Review 10.  A systematic review of hip fracture incidence and probability of fracture worldwide.

Authors:  J A Kanis; A Odén; E V McCloskey; H Johansson; D A Wahl; C Cooper
Journal:  Osteoporos Int       Date:  2012-03-15       Impact factor: 4.507

View more
  15 in total

1.  Use of antiosteoporotic drugs and calcium/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk.

Authors:  Luca Degli Esposti; Anna Girardi; Stefania Saragoni; Stefania Sella; Margherita Andretta; Maurizio Rossini; Sandro Giannini
Journal:  Endocrine       Date:  2018-12-04       Impact factor: 3.633

2.  Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO.

Authors:  L Vignozzi; N Malavolta; P Villa; G Mangili; S Migliaccio; S Lello
Journal:  J Endocrinol Invest       Date:  2018-11-19       Impact factor: 4.256

Review 3.  Adverse effects of media reports on the treatment of osteoporosis.

Authors:  Cristiana Cipriani; Jessica Pepe; Salvatore Minisola; E Michael Lewiecki
Journal:  J Endocrinol Invest       Date:  2018-05-14       Impact factor: 4.256

4.  Association between renal function and bone mineral density in healthy postmenopausal Chinese women.

Authors:  Shuang Li; Junkun Zhan; Yanjiao Wang; Yi Wang; Jieyu He; Wu Huang; Zhifeng Sheng; Youshuo Liu
Journal:  BMC Endocr Disord       Date:  2019-12-26       Impact factor: 2.763

5.  Oxidative Stress Contributes to Hyperalgesia in Osteoporotic Mice.

Authors:  Chen Tu; Di-Zheng Wu; Yu-Sheng Huang; Jing-Shen Zhuang; Ji-Huan Zeng; Ping Xu; Ting-Ting Meng; Zhao-Ming Zhong
Journal:  J Pain Res       Date:  2020-01-15       Impact factor: 3.133

6.  Insight into the roles of melatonin in bone tissue and bone‑related diseases (Review).

Authors:  Xiaofeng Lu; Shaoling Yu; Guangjin Chen; Wenhao Zheng; Jinfeng Peng; Xiaofei Huang; Lili Chen
Journal:  Int J Mol Med       Date:  2021-03-24       Impact factor: 4.101

7.  Lumbar spine bone mineral density and trabecular bone score-adjusted FRAX, but not FRAX without bone mineral density, identify subclinical carotid atherosclerosis.

Authors:  J Pepe; G Della Grotta; R Santori; V De Martino; M Occhiuto; M Cilli; S Minisola; C Cipriani
Journal:  J Endocrinol Invest       Date:  2021-02-12       Impact factor: 4.256

8.  Gut microbiota and metabolite alterations associated with reduced bone mineral density or bone metabolic indexes in postmenopausal osteoporosis.

Authors:  Jianquan He; Shuangbin Xu; Bangzhou Zhang; Chuanxing Xiao; Zhangran Chen; Fuyou Si; Jifan Fu; Xiaomei Lin; Guohua Zheng; Guangchuang Yu; Jian Chen
Journal:  Aging (Albany NY)       Date:  2020-05-11       Impact factor: 5.682

9.  Association between Hypertension, Antihypertensive Drugs, and Osteoporosis in Postmenopausal Syrian Women: A Cross-Sectional Study.

Authors:  Nermeen Hijazi; Zaynab Alourfi
Journal:  Adv Med       Date:  2020-02-19

10.  Are women with osteoporosis treated with denosumab at risk of severe COVID-19?

Authors:  Anna Maria Formenti; Erika Pedone; Luigi di Filippo; Fabio Massimo Ulivieri; Andrea Giustina
Journal:  Endocrine       Date:  2020-09-20       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.